a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia.
b National Ageing Research Institute , Melbourne , VIC , Australia.
J Clin Exp Neuropsychol. 2019 Aug;41(6):591-600. doi: 10.1080/13803395.2019.1593949. Epub 2019 Mar 29.
: Preclinical Alzheimer's disease (AD) is characterized by amyloid-related cognitive decline. Reduction in this decline is used to determine the efficacy of drug therapies designed to forestall the disease in preclinical AD clinical trials, measured by a Preclinical Alzheimer's Cognitive Composite (PACC). Most studies estimate rates of cognitive change by comparing cognitively normal (CN) older adults with abnormally high beta-amyloid (Aβ+) to those with low levels (Aβ-). However, participants of preclinical AD clinical trials must be Aβ+ for entry. Therefore, we estimated the effect of very high amyloid (Aβ++) and Aβ+ on cognitive change over three years measured by different versions of the PACC in individuals with preclinical AD. : CN older adults underwent Aβ neuroimaging and neuropsychological assessments over three years as part of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Three cognitive composite scores were computed: the Alzheimer's Disease Cooperative Study (ADCS)-PACC, the ADCS-PACC with no Mini-Mental State Examination (MMSE), and the -scores of Attention, Verbal Fluency and Episodic Memory for Nondemented Older Adults (ZAVEN) composite. : Compared to the Aβ++ group, the Aβ+ group showed a slower rate of cognitive decline with the largest magnitude of difference reflected by the ADCS-PACC ( = 0.85). The ADCS-PACC excluding the MMSE and the ZAVEN also reflected a moderate to large magnitude of difference between groups ( = 0.62, = 0.72, respectively). : When all individuals have abnormal Aβ, the level of Aβ at baseline is associated with the rate of subsequent decline. The ADCS-PACC was the most sensitive composite score in showing that lower Aβ is associated with a slower rate of cognitive decline; however, there are limitations to the use of the MMSE. These results provide a benchmark of comparison for preclinical AD clinical trials aiming to slow cognitive deterioration.
: 临床前阿尔茨海默病(AD)的特征是与淀粉样蛋白相关的认知能力下降。在临床前 AD 临床试验中,通过临床前阿尔茨海默病认知综合评分(PACC)来衡量,降低这种下降速度可以确定旨在预防疾病的药物疗法的疗效。大多数研究通过比较认知正常(CN)老年人中β-淀粉样蛋白(Aβ+)水平较高者与水平较低者(Aβ-)来估计认知变化率。然而,临床前 AD 临床试验的参与者必须是 Aβ+才能入组。因此,我们在临床前 AD 患者中,根据不同版本的 PACC,估计了非常高的淀粉样蛋白(Aβ++)和 Aβ+对三年内认知变化的影响。: CN 老年人作为澳大利亚成像、生物标志物和生活方式(AIBL)研究的一部分,在三年内接受了 Aβ 神经影像学和神经心理学评估。计算了三个认知综合评分:阿尔茨海默病合作研究(ADCS)-PACC、不包括简易精神状态检查(MMSE)的 ADCS-PACC 和用于非痴呆老年人的注意力、言语流畅性和情景记忆评分(ZAVEN)综合评分。: 与 Aβ++组相比,Aβ+组的认知衰退速度较慢,ADCS-PACC 反映的差异最大( = 0.85)。不包括 MMSE 和 ZAVEN 的 ADCS-PACC 也反映了两组之间的中等至较大差异( = 0.62, = 0.72)。: 当所有个体的 Aβ 均异常时,基线时的 Aβ 水平与随后的下降速度相关。ADCS-PACC 是最敏感的综合评分,表明较低的 Aβ 与认知衰退速度较慢相关;然而,简易精神状态检查的使用存在局限性。这些结果为旨在减缓认知恶化的临床前 AD 临床试验提供了比较基准。